Related Experiment Video
Updated: Mar 3, 2026

Murine Full-thickness Skin Transplantation
Published on: January 2, 2017
Cutaneous Toxicities From Transplantation-Related Medications
M Ilyas1, O R Colegio2, B Kaplan3
1Department of Dermatology, Mayo Clinic Arizona, Scottsdale, AZ.
Abstract:
Despite the abundance of information on cutaneous malignancies associated with solid organ transplantation in the transplant literature, there is limited information regarding nonmalignant skin changes after transplantation. There are numerous skin toxicities secondary to immunosuppressive and other transplant-related medications that can vary in presentation, severity, and prognosis. To limit associated morbidity and mortality, solid organ transplant recipient care providers should effectively identify and manage cutaneous manifestations secondary to drug toxicity. Toxicities from the following transplant-related medications will be discussed: antithymocyte globulins, systemic steroids, cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, mammalian target of rapamycin inhibitors sirolimus and everolimus, basiliximab and daclizumab, belatacept, and voriconazole.
Insights
Solid organ transplant recipients often experience nonmalignant skin changes due to medications. Early identification and management of these drug toxicities are crucial for patient care.
Area of Science:
- Dermatology
- Transplantation Medicine
- Pharmacology
Background:
- Limited data exists on nonmalignant skin changes post-solid organ transplantation.
- Skin toxicities are common adverse effects of immunosuppressive and transplant-related medications.
Purpose of the Study:
- To review and discuss nonmalignant cutaneous manifestations of transplant-related medications.
- To provide guidance for identifying and managing drug-induced skin toxicities in transplant recipients.
Main Methods:
- Literature review of transplant-related medications and their dermatologic side effects.
- Discussion of specific drug classes including antithymocyte globulins, systemic steroids, calcineurin inhibitors, antiproliferatives, mTOR inhibitors, and others.
Main Results:
- Various immunosuppressive and anti-rejection drugs can cause a spectrum of nonmalignant skin conditions.
- Understanding the presentation, severity, and prognosis of these toxicities is essential.
Conclusions:
- Effective management of drug-induced skin toxicities is vital to reduce morbidity in solid organ transplant recipients.
- Healthcare providers must be vigilant in recognizing and treating these dermatologic side effects.
Related Concept Videos
Drug Toxicity: Allergic Reactions
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Cell-mediated Immune Responses
Kidney Transplant III: Nursing Management
Kidney Transplant II: Surgical Procedure
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...

